Logo
AI Document Review
Free
Comparison
Free
PII Redaction
Free
Pricing
Sign inSign up

AI Contract Review for Pharmaceutical & Biotechnology Industry

Backed by Microsoft For Startups
Guided by Grayver Law Group
AES-256 Encryption
Personal (PII) & Corporate Data Redacted Before AI
Free during early access

Pharmaceutical contract review is critical for biotechnology companies facing stringent FDA regulations requiring detailed contract oversight for manufacturing, clinical trials, and supplier relationships. Justee AI helps ensure compliance with 21 CFR Part 211, cGMP requirements, and quality agreement standards in minutes.

Free and no sign-up required.

Get Your Free Document Review

Federal only

Your data is protected at every layer

No file selected

Protected by reCAPTCHA. Privacy · Terms

Guest uploads are automatically deleted within 24 hours

Key Takeaways

Review CMO and supplier quality agreements for FDA 21 CFR Part 211 compliance

Identify gaps in clinical trial agreements that could impact regulatory submissions

Ensure contract manufacturing arrangements meet cGMP requirements and define clear responsibilities

Verify regulatory compliance obligations are properly allocated between parties

1-2 minutes*

Average Review Time

62+ FDA and cGMP compliance checks*

Compliance Checks

SOC 2 Type II, HIPAA compliant

Document Security

* Estimates based on typical documents. Actual results vary by document type and complexity.

The FDA requires pharmaceutical companies to maintain ultimate responsibility for product quality even when manufacturing is outsourced to Contract Manufacturing Organizations (CMOs). Under 21 CFR Part 211 and cGMP regulations, sponsors must ensure written quality agreements define specifications, responsibilities, and compliance protocols. FDA warning letters increased 50% in FY2025, with contract manufacturing oversight cited as a common deficiency. Quality agreements must specify manufacturing specifications, batch release procedures, change control processes, CAPA protocols, and regulatory inspection rights. The average cost of FDA non-compliance reached $14.8 million per violation by 2026, making contract compliance review essential. Clinical trial agreements must clearly define sponsor and CRO responsibilities under ICH-GCP guidelines to avoid regulatory delays that can cost $600,000 to $8 million per day in lost revenue.

Key Industry Regulations

FDA 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals

FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures

ICH-GCP (E6) - Good Clinical Practice guidelines for clinical trials

FDA Guidance on Contract Manufacturing Arrangements for Drugs

FSMA - Food Safety Modernization Act requirements

FDA 21 CFR Part 312 - Investigational New Drug Applications

ICH Q7 - Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients

How It Works

1
Upload Your Contract

Upload your contract in PDF, DOCX, or TXT format

2
AI Analysis

Our AI reviews for industry-specific compliance issues

3
Review Findings

Get detailed findings with regulatory citations

4
Take Action

Use our suggestions to improve compliance

What We Check

FDA regulatory compliance verification - ensures contracts align with 21 CFR Part 211 and cGMP requirements

Quality agreement review - validates CMO agreements specify manufacturing standards, batch release, and CAPA procedures

Clinical trial contract analysis - verifies CRO agreements define GCP compliance, regulatory responsibilities, and reporting obligations

Supplier quality agreement assessment - confirms component suppliers meet pharmaceutical-grade specifications and traceability requirements

Regulatory inspection rights - ensures contracts grant necessary audit and inspection access for FDA compliance

Common Risks We Identify

Inadequate quality agreement terms failing to specify cGMP compliance responsibilities, exposing sponsors to FDA enforcement

Missing batch release procedures in CMO contracts that could delay product launches and regulatory approvals

Ambiguous regulatory responsibility clauses in clinical trial agreements leading to compliance gaps during FDA audits

Insufficient change control provisions allowing unauthorized manufacturing modifications without sponsor approval

Weak indemnification language failing to protect against CMO non-compliance that triggers FDA warning letters

Common Industry Documents

Quality Agreement (CMO)

Defines manufacturing standards, specifications, and cGMP compliance responsibilities

Clinical Trial Agreement

Establishes sponsor and CRO responsibilities for GCP-compliant research

Supplier Quality Agreement

Specifies component quality standards and pharmaceutical-grade requirements

Contract Manufacturing Agreement

Governs outsourced production with regulatory compliance terms

Master Services Agreement

Framework agreement for ongoing pharmaceutical services and testing

Hypothetical Case Study by Justee

Justee recently analyzed a contract manufacturing agreement with a CMO in Europe for commercial-scale production for a mid-sized biotech company in San Diego developing oncology therapeutics.

Issue Found: The agreement failed to specify who was responsible for investigating deviations during manufacturing, and the batch release procedures did not clearly define quality control testing authority

Justee Recommendation: We revised the agreement to explicitly assign deviation investigation responsibility to the CMO with sponsor notification within 24 hours, and added detailed batch release procedures requiring both parties' QA approval before commercial distribution, preventing potential FDA compliance issues

Inadequate Quality Agreement Specification

Problematic Language

"Manufacturer shall produce the Product in accordance with cGMP and applicable regulations. Manufacturer is responsible for quality control of the Product."

Recommended Language

"Manufacturer shall produce the Product in strict accordance with FDA 21 CFR Part 211, ICH Q7, and the specifications detailed in Exhibit A. Manufacturer shall maintain a quality agreement pursuant to FDA guidance that specifies: (a) manufacturing process controls and in-process testing, (b) batch record review and approval procedures, (c) deviation investigation and CAPA protocols with Sponsor notification within 24 hours, (d) change control requiring written Sponsor approval, and (e) annual product quality review procedures."

Why it matters: The original language is dangerously vague. FDA considers the sponsor ultimately responsible for cGMP compliance even with outsourced manufacturing. Without detailed specifications, batch release procedures, deviation protocols, and change control requirements, the sponsor has no contractual protection if the CMO's practices fail FDA inspection. The revised language creates enforceable compliance obligations aligned with FDA expectations for contract manufacturing oversight.

No credit card required

"Justee is redefining the legal document compliance process across all practice areas, transforming hours of work into minutes, while reducing stress and boosting accuracy."

Artem Dolukhanyan
Artem Dolukhanyan

Partner, Corporate Transactions at Grayver Law Group

AI Review vs. Manual Review

FeatureJustee AI ReviewManual Review
Review Time1-2 minutes*2-4 hours
CostFree trial available$300-800+
Regulatory Coverage62+ FDA and cGMP compliance checks*Varies by reviewer
Clause SuggestionsIncludedExtra fee
Availability24/7 instantBusiness hours
* Comparison data represents estimates based on industry research and internal testing for typical contract types. Review times, costs, and accuracy percentages vary by document complexity, length, jurisdiction, and specific legal requirements. See full disclaimer below.

Official Regulatory Resources

FDA Guidance on Contract Manufacturing

Official FDA guidance on contract manufacturing arrangements and quality agreements

FDA 21 CFR Part 211 - cGMP Requirements

Current Good Manufacturing Practice regulations for finished pharmaceuticals

ICH Good Manufacturing Practice Guidelines

International Conference on Harmonisation quality standards for pharmaceutical manufacturing

Related Industry Reviews

Healthcare Contract ReviewMedical Device Contract ReviewClinical Research Contract ReviewManufacturing Contract ReviewQuality Agreement Review
Important Legal Disclaimer

Not Legal Advice: The information and analysis provided by Justee AI is for general informational purposes only and does not constitute legal advice. While we strive to provide accurate and helpful information, our AI-powered service is not a substitute for professional legal counsel.

No Attorney-Client Relationship: Use of Justee AI does not create an attorney-client relationship. Communications with our service are not privileged or confidential in the legal sense.

Consult a Professional: For specific legal matters, we strongly recommend consulting with a qualified attorney licensed in your jurisdiction. Legal requirements vary by location and circumstances, and only a licensed attorney can provide advice tailored to your specific situation.

Performance Estimates (*): All statistics, metrics, and numerical claims on this page — including review times, cost comparisons, accuracy percentages, and database size — are estimates based on internal testing, industry research, and typical use cases. Actual results vary based on document type, complexity, length, jurisdiction, and other factors. Cost comparisons reference publicly available average attorney rates and are not guaranteed savings. "1M+ laws and regulations" refers to the breadth of Justee's reference database and does not imply that every provision is checked against every law for every document.

By using our service, you acknowledge that you have read and agree to our Terms of Use and understand the limitations of AI-powered legal analysis. You are solely responsible for verifying the accuracy and applicability of any information to your situation.

Frequently Asked Questions

The most critical clauses are: (1) Quality agreement specifications defining cGMP compliance responsibilities, (2) Batch release procedures requiring QA approval from both parties, (3) Deviation investigation protocols with 24-hour notification requirements, (4) Change control processes requiring written sponsor approval for any manufacturing modifications, (5) Regulatory inspection rights allowing sponsor and FDA access to facilities, and (6) Indemnification provisions protecting sponsors from CMO non-compliance. FDA considers sponsors ultimately responsible even for outsourced manufacturing.

FDA holds sponsor companies ultimately responsible for product quality even when manufacturing is outsourced. During inspections, FDA reviews quality agreements and expects to see detailed written procedures covering specifications, batch release, deviations, change control, and CAPA. If a CMO fails to meet cGMP standards, FDA can issue warning letters to both the CMO and the sponsor. The average compliance violation cost reached $14.8 million in 2026. Sponsors must have contractual audit rights and oversight mechanisms to demonstrate adequate CMO supervision.

A supplier quality agreement should include: (1) Material specifications with acceptance criteria and testing protocols, (2) Certificate of Analysis (CoA) requirements for each lot, (3) Change notification procedures requiring advance approval for any modifications to materials or processes, (4) Audit rights allowing inspection of supplier facilities and records, (5) Traceability and recall procedures, (6) Regulatory compliance certifications (cGMP, GDP), and (7) Deviation and complaint handling procedures. These agreements ensure pharmaceutical-grade raw materials meet FDA standards.

Clinical trial agreements focus on GCP compliance, protocol adherence, patient safety, and regulatory reporting under ICH-GCP guidelines and 21 CFR Part 312. They define sponsor and CRO responsibilities for informed consent, IRB/ethics committee submissions, adverse event reporting, data management, and regulatory inspections. Commercial manufacturing agreements emphasize cGMP compliance under 21 CFR Part 211, batch release procedures, quality systems, and commercial-scale production. Both require clear regulatory responsibility allocation, but clinical agreements prioritize patient protection while commercial agreements prioritize product quality.

Justee AI is purpose-built for pharmaceutical & biotech contract review, with a regulatory checklist trained on FDA 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals and adjacent rules. Generic AI tools surface obvious issues like missing signatures or vague terms; Justee AI flags industry-specific compliance gaps — risk allocation, regulatory responsibility, audit and inspection rights, and indemnification language calibrated to pharmaceutical & biotech sector exposure. Every review is fast, secure, and produces a redlined contract with a plain-English explanation of why each clause matters.

Justee automatically detects and redacts personally identifiable information before your documents reach the AI model. Protected types include:

Personal data:
  • Names, email addresses, and phone numbers
  • Social Security numbers and tax identifiers (ITIN)
  • Physical addresses and dates of birth
  • Credit card and bank account numbers
  • Driver's license and passport numbers
  • Medical provider identifiers (NPI) and case numbers
Corporate and business data:
  • Company and organization names
  • Business addresses and geographic locations
  • SWIFT/BIC codes, IBAN numbers, and bank routing numbers
  • Business license numbers and attorney bar IDs
  • Corporate tax identifiers (EIN)
Our system achieves 100% detection of standard PII types and approximately 97% overall coverage. Certain rare identifiers — such as cryptocurrency wallet addresses and MAC addresses — may not be detected automatically. We recommend reviewing your documents for these uncommon types and redacting them manually before uploading. See our Privacy Policy and Terms of Use for details and limitations.

Ready to Review Your Contract?

Upload your contract above to get started. No sign-up required.

Need more reviews? Create a free account

Last updated: May 13, 2026

Privacy

Legal

Terms of servicePrivacy policy

About

About usContactsBlogAffiliate program

Follow us

LinkedIn
logo

© 2026 Justee. All rights reserved.